Jpmorgan Chase & CO Ventyx Biosciences, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VTYX
# of Institutions
125Shares Held
52.9MCall Options Held
35.3KPut Options Held
83K-
Deerfield Management Company, L.P. (Series C) New York, NY6.72MShares$12.4 Million0.27% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$8.83 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.46MShares$8.24 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$6.42 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$5.86 Million0.03% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $105M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...